Results
1 -
10 of
32Neue orale Antidiabetika, Der Internist Effects of Thiazolidinediones on Serum Lipoproteins, Therapeutic Lipidology Safety of PPAR Agonists, Peroxisome Proliferator-Activated Receptors Dual Acting and Pan-PPAR Activators as Potential Anti-diabetic Therapies, Diabetes - Perspectives in Drug Therapy Mayday for Dual PPAR Agonists, Pharmaceutical & Diagnostic Innovation Allometric prediction of the human pharmacokinetic parameters for naveglitazar, European Journal of Drug Metabolism and Pharmacokinetics Perspective: Effect of rosiglitazone on cardiovascular outcomes, Current Cardiology Reports The US Food and Drug Administration: A dysfunctional agency in need of major reforms, Current Cardiology Reports The market in diabetes, Diabetologia Pioglitazone in Clinical Practice: Where Are We Now?, Diabetes Therapy